论文部分内容阅读
目的探讨阻抑蛋白在肝硬化和原发性肝癌(肝癌)组织中的表达及临床病理学意义。方法采用免疫组织化学EnVision法检测阻抑蛋白在32例肝癌组织、19例肝硬化组织和21例对照肝组织标本中的表达,并分析其与临床病理参数的相关性。结果肝癌组阻抑蛋白阳性表达率为100%,高于肝硬化组的78.95%和对照组的80.95%(P<0.05);肝癌组织中阻抑蛋白的表达与患者的性别、年龄、肿瘤大小、肿瘤数目、肿瘤有无坏死、门静脉有无癌栓、肿瘤分化程度、肿瘤的临床分期和TNM分期均无关(P>0.05)。结论阻抑蛋白参与了肝癌的发生发展过程,对于小肝癌的诊断可能具有一定的临床应用价值。
Objective To investigate the expression of repressor protein in cirrhosis and primary hepatocellular carcinoma (HCC) and its clinicopathological significance. Methods EnVision immunohistochemistry was used to detect the expression of repressor protein in 32 specimens of HCC, 19 specimens of cirrhosis and 21 specimens of control liver tissues. The correlation between them and clinicopathological parameters was analyzed. Results The expression of repressor protein in hepatocellular carcinoma was 100%, higher than that of cirrhosis (78.95%) and control group (80.95%) (P <0.05). The expression of repressor protein in hepatocellular carcinoma was significantly correlated with the gender, age, tumor size , Tumor number, tumor necrosis, portal vein tumor thrombus, tumor differentiation, clinical stage and TNM stage (P> 0.05). Conclusion The repressor protein is involved in the occurrence and development of hepatocellular carcinoma, which may have some clinical value for the diagnosis of small hepatocellular carcinoma.